Extended Long-Term Safety Study of KW-6500

Summary

This is a extended long-term safety study in Parkinson's disease patients who have motor response complications on levodopa therapy and completed 12 weeks administrations of KW-6500 in 6500-004 study. The safety and efficacy of long-term subcutaneous self-injections of KW-6500 are evaluated.

Timeline

Start

2010-01

Primary completion

2011-08

Completion

2012-03

Drugs

Indications